Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 15/20 | 0.60 |
| ▸ | RAB9A | P51151 | 14/20 | 0.60 |
| ▸ | TAF1 | P21675 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402413 | 0.81 | TAF1 (0.65) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL20942542 | 0.81 | TAF1 (0.65) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL20942497 | 0.81 | NPC1 (0.58) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL19276664 | 0.80 | SMN1; SMN2 (0.70) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL20942575 | 0.80 | NPC1 (0.58) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL20942536 | 0.77 | TAF1 (0.60) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL20942496 | 0.76 | RAB9A (0.64) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL20942538 | 0.74 | NPC1 (0.60) | NPC1RAB9ATAF1TP53SMN1; SMN2 | |
| SCHEMBL19276604 | 0.74 | RAB9A (0.56) | NPC1RAB9ATP53SMN1; SMN2MAPT | |
| SCHEMBL20942221 | 0.74 | TAF1 (1.00) | NPC1RAB9ATAF1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702518-B2 | TAF1 inhibitors for the therapy of cancer | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH (AT) | 2020-07-07 | — | — | US | disclosed |
| US-20190117641-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2019-04-25 | — | — | US | disclosed |
| WO-2017140728-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117641-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | TAF1, TAF1L, TAF5 | NPC1 2981/4885RAB9A 3061/4885TAF1 1/4885 |
| US-10702518-B2 | TAF1 inhibitors for the therapy of cancer | TAF1, TAF1L, TAF5 | NPC1 2981/4885RAB9A 3061/4885TAF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.